These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 31564170)

  • 1. Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia.
    Marteene W; Winckel K; Hollingworth S; Kisely S; Gallagher E; Hahn M; Ebdrup BH; Firth J; Siskind D
    Expert Opin Drug Saf; 2019 Dec; 18(12):1149-1160. PubMed ID: 31564170
    [No Abstract]   [Full Text] [Related]  

  • 2. Schizophrenia, obesity, and antipsychotic medications: what can we do?
    Citrome L; Vreeland B
    Postgrad Med; 2008 Jul; 120(2):18-33. PubMed ID: 18654065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic induced weight gain in schizophrenia:mechanisms and management.
    Rege S
    Aust N Z J Psychiatry; 2008 May; 42(5):369-81. PubMed ID: 18473255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of schizophrenia with obesity, metabolic, and endocrinological disorders.
    Monteleone P; Martiadis V; Maj M
    Psychiatr Clin North Am; 2009 Dec; 32(4):775-94. PubMed ID: 19944883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topiramate's effectiveness on weight reduction in overweight/obese persons with schizophrenia: study protocol for a randomized controlled trial.
    Chandradasa M; Champika L; de Silva S; Kuruppuarachchi KALA
    Trials; 2017 Sep; 18(1):435. PubMed ID: 28931411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain.
    Ellinger LK; Ipema HJ; Stachnik JM
    Ann Pharmacother; 2010 Apr; 44(4):668-79. PubMed ID: 20233913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment.
    Cooper SJ; Reynolds GP; ; Barnes T; England E; Haddad PM; Heald A; Holt R; Lingford-Hughes A; Osborn D; McGowan O; Patel MX; Paton C; Reid P; Shiers D; Smith J
    J Psychopharmacol; 2016 Aug; 30(8):717-48. PubMed ID: 27147592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schizophrenia and obesity: impact of antipsychotic medications.
    Wirshing DA
    J Clin Psychiatry; 2004; 65 Suppl 18():13-26. PubMed ID: 15600381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia.
    Weiden PJ
    J Clin Psychiatry; 2007; 68 Suppl 4():34-9. PubMed ID: 17539698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic complications of schizophrenia and antipsychotic medications--an updated review.
    Yogaratnam J; Biswas N; Vadivel R; Jacob R
    East Asian Arch Psychiatry; 2013 Mar; 23(1):21-8. PubMed ID: 23535629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjunctive α-lipoic acid reduces weight gain compared with placebo at 12 weeks in schizophrenic patients treated with atypical antipsychotics: a double-blind randomized placebo-controlled study.
    Kim NW; Song YM; Kim E; Cho HS; Cheon KA; Kim SJ; Park JY
    Int Clin Psychopharmacol; 2016 Sep; 31(5):265-74. PubMed ID: 27276401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of weight gain in patients with schizophrenia.
    Aquila R
    J Clin Psychiatry; 2002; 63 Suppl 4():33-6. PubMed ID: 11913674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia.
    McIntyre RS; Trakas K; Lin D; Balshaw R; Hwang P; Robinson K; Eggleston A
    Can J Psychiatry; 2003 Nov; 48(10):689-94. PubMed ID: 14674052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review.
    Martínez-Ortega JM; Funes-Godoy S; Díaz-Atienza F; Gutiérrez-Rojas L; Pérez-Costillas L; Gurpegui M
    Eur Child Adolesc Psychiatry; 2013 Aug; 22(8):457-79. PubMed ID: 23503976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents.
    Maayan L; Correll CU
    J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):517-35. PubMed ID: 22166172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
    Mukundan A; Faulkner G; Cohn T; Remington G
    Cochrane Database Syst Rev; 2010 Dec; (12):CD006629. PubMed ID: 21154372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of antipsychotic medications on microbiome and weight gain in children and adolescents.
    Bretler T; Weisberg H; Koren O; Neuman H
    BMC Med; 2019 Jun; 17(1):112. PubMed ID: 31215494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the effect of atypical antipsychotics on weight.
    Nasrallah H
    Psychoneuroendocrinology; 2003 Jan; 28 Suppl 1():83-96. PubMed ID: 12504074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.